CYP21A2 and congenital adrenal hyperplasia: The patients were categorized based on CYP21A2 genotype: (1) 65% (n = 26) of patients without CYP21A2 mutation, (2) 15% (n = 6) of patients with a mutation in one allele CYP21A2, (3) 10% (n = 4 homozygotes and NC-CAH) of patients with two pathogenic alleles, and 2.5% (n = 1 compound heterozygote) and (4) 10% (n = 4) of patients with regulatory variants (Table 1).